Tagged with Angelini

Italy A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC Pharma; Menarini’s oncology partnership with Insilico Medicine, and Angelini’s brain health deal with Cureverse.   Italian drug maker Recordati boosts…

Switzerland Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of patients in Switzerland, but the country’s status as a global biopharmaceutical R&D hub?   Major Challenges As outlined elsewhere in…

Switzerland Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational firms. Over 0.5 percent of the entire Swiss population (48,000 out of 8.8 million) work in the life sciences, 67…

Switzerland Hendrik von Waldburg, Country Manager of Angelini Pharma S.p.A., Rom, Zweigniederlassung Zug, shares insights into the company’s ambitious vision for brain health and its expanding presence in the Swiss market. With a strong background in CNS and a focus on innovative therapies, Hendrik discusses the challenges and opportunities of building…

Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…

Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…

Greece Angelini Pharma’s Gabriele Jannis draws on his experience in both Russia and Romania to highlight some of the key challenges for European mid-caps like Angelini in Greece, the importance of CEE countries in the company’s internationalisation efforts, and his hopes for future reform that increases the level of certainty in…

Italy After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive.   [I am] looking forward to joining the Angelini team and helping to chart the next chapter for [Angelini] Pharma. Jacopo Andreose Abrupt…

Italy Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap.   Antonelli, profiled by PharmaBoardroom earlier this year, had been in position since 2019 having previously worked his way through the ranks…

Italy Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the move and the main components of the company’s transformational journey.   Rather than continue on the perhaps easier path he…

Italy Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma’s progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of Angelini’s USD 960 million Arvelle acquisition, why he is optimistic about success in the challenging brain health space, and how…

Italy The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of Menarini’s Europe commercialisation deal for Karyopharm’s NEXPOVIO in Europe.   Angelini Pharma Appoints Rafal Kaminski as New Chief Scientific Officer…